TMA-6

Discovery

TMA-6 was first synthesized in the early 1950s as part of systematic investigations into mescaline structural analogs.citation needed Alexander Shulgin independently discovered its psychedelic properties in 1964 through self-experimentation. Working with Thornton Sargent and Claudio Naranjo, Shulgin conducted dose-response studies across the TMA positional isomers, publishing results in a 1969 Nature paper that established the first systematic potency comparison of the series.^[2]

Scientific Contribution

TMA-6's significance is primarily as a structure-activity reference point. The symmetric 2,4,6-trimethoxy substitution pattern provides a distinct data point against mescaline's 3,4,5-arrangement and TMA-2's 2,4,5-arrangement. Shulgin documented the compound as entry #162 in PiHKAL (1991),^[5] describing it as "one of the most rewarding and pleasurable of the methoxylated amphetamines" and proposing it as a template for generating new analog series.^[3]

Prohibition and Modern Status

TMA-6 has appeared on grey-market research chemical markets, though less widely than TMA-2. Its detection in forensic samples prompted development of LC-MS assays for identification in biological matrices.^[6][7] No clinical trials have been registered, and TMA-6 remains scheduled in multiple jurisdictions as a positional isomer of trimethoxyamphetamine.

Structural Overview

TMA-6 (2,4,6-trimethoxyamphetamine) is built on the amphetamine scaffold — a phenylisopropylamine backbone — with three methoxy (−OCH₃) groups placed symmetrically at the 2, 4, and 6 positions of the aromatic ring. This "phloroglucinol" substitution pattern distinguishes it from all other TMA isomers: mescaline carries the 3,4,5-trimethoxy pattern on phenethylamine, while TMA-2 uses the 2,4,5-arrangement on the amphetamine scaffold.

The alpha-methyl group (the amphetamine side chain) differentiates TMA-6 from its phenethylamine counterpart. This structural feature confers greater metabolic stability, improved oral bioavailability, and extended duration of action. Phenylisopropylamines are also more efficacious than their phenethylamine counterparts at 5-HT₂A receptors.^[8]

The three methoxy groups create a sterically crowded aromatic environment, with both ortho positions flanking the side-chain attachment occupied — a configuration that influences how the molecule fits into receptor binding sites and how readily liver enzymes access it for breakdown.

Stereochemistry

TMA-6 has a single chirality center at the alpha-carbon. The commercially available form is a racemic mixture. Within the phenylisopropylamine psychedelic class, the (R)-enantiomer is generally the more pharmacologically active stereoisomer at 5-HT₂A receptors.^[4] No enantioselectivity studies specific to TMA-6 have been published; the active enantiomer is presumed to be (R) by structural analogy.

Physical Properties

The hydrochloride salt melts at 207–208 °C.^[9] As a methoxylated amphetamine, the free base is expected to be a lipophilic oil; the hydrochloride salt is a white to off-white crystalline solid suitable for oral administration.

Mechanism of Action

TMA-6 activates the serotonin 5-HT₂A receptor — the primary molecular target behind classical psychedelic effects.^[4] A reported potency value (EC₅₀ = 29.2 nM) with full efficacy relative to serotonin has been attributed to the Luethi/Liechti research group, though the specific primary publication was not located during literature review.^[1]safety citation needed Related studies from the same group characterized other mescaline derivatives and TMA-2 but did not directly report TMA-6 data.^[10][11]

TMA-6 also inhibits MAO-A (MAO-A) with a reported IC₅₀ of approximately 400 nM.^[1]safety citation needed This dual mechanism is pharmacologically distinctive: MAO-A breaks down serotonin, so inhibiting it raises serotonin levels in the synapse while the compound simultaneously activates 5-HT₂A receptors directly. The result is an amplified and prolonged psychedelic effect. This MAO-A inhibitory activity is consistent with the broader pharmacology of methoxylated amphetamines.^[12][13]

TMA-6 does not release or block reuptake of dopamine, serotonin, or norepinephrine — it is inactive at monoamine transporters.^[14] It also shows no meaningful binding at 5-HT₁A or dopamine D₂ receptors.^[1]

Pharmacokinetics

No human pharmacokinetic data have been published for TMA-6. Absorption, distribution, metabolism, and elimination parameters remain uncharacterized in any controlled study.

Community sources report onset at 30–90 minutes after oral ingestion,^[15] consistent with oral absorption of the amphetamine backbone. The total duration of 12–16 hours^[3] is prolonged relative to most phenethylamine psychedelics and likely reflects a combination of receptor occupancy, MAO-A inhibition slowing serotonin breakdown, and slow liver clearance.^[15]

The three methoxy groups are probable sites for metabolic breakdown via liver enzymes, producing catechol metabolites.inferred The compound's own MAO-A inhibitory activity may slow its own metabolism, potentially contributing to the prolonged duration.

Where It Acts

No direct neuroimaging or electrophysiology data exist for TMA-6. All neural mechanism descriptions are inferred from its pharmacological profile and the well-characterized neuroscience of serotonergic psychedelics.inferred As a serotonin 2A receptor agonist, TMA-6 is expected to activate deep-layer neurons in the prefrontal cortex — the cellular trigger for psychedelic effects established across LSD, psilocybin, and mescaline.^[4] Predicted downstream effects include reduced default mode network connectivity (associated with ego dissolution), disrupted sensory gating through the thalamus (underlying perceptual effects), and increased cross-network communication.

The MAO-A inhibitory component adds a dimension absent from most classical psychedelics: elevated serotonin across all receptor subtypes, not just 5-HT₂A activation. This could amplify inhibitory 5-HT₁A effects at high serotonin concentrations, potentially modulating the experience in ways distinct from pure 5-HT₂A agonists.

Why It Matters

The REBUS (Relaxed Beliefs Under Psychedelics) model proposes that psychedelics flatten the brain's confidence in its existing assumptions, allowing raw sensory information greater influence on conscious experience. TMA-6's reported full agonism at 5-HT₂A would predict strong effects under this model. Whether TMA-6 promotes structural neuroplasticity — as other serotonergic psychedelics do via BDNF and mTOR signaling — is unknown, and the concurrent MAO-A inhibition could modulate any neuroplastic response in unpredictable ways.

Toxicity

No lethal dose has been established for TMA-6 in any species. No therapeutic index has been calculated. No human fatalities attributed solely to TMA-6 appear in the published medical literature, though the compound's rarity limits meaningful conclusions from this absence.

Serotonin Syndrome Risk

If the reported MAO-A IC₅₀ of ~400 nM is accurate,^[1]safety citation needed TMA-6 inhibits the primary serotonin-degrading enzyme with clinically meaningful potency at active psychedelic doses.

Psychological Risks

Like all classical serotonergic psychedelics, TMA-6 carries risk of acute anxiety, paranoia, challenging psychological experiences, and psychotic episodes in vulnerable individuals. No peer-reviewed literature on TMA-6-specific psychological risks exists.

Shulgin's PiHKAL reports include one participant's account of "a strange mixture of plateaus, exuberance, and strong negative feelings".^[3] The prolonged duration (12–16 hours) amplifies psychological risk: a challenging experience cannot be waited out within a normal waking period, and fatigue over the extended time course may erode psychological resilience.

Tolerance and Dependence

Tolerance develops rapidly through 5-HT₂A downregulation, consistent with all classical serotonergic psychedelics.^[4] Community sources report a tolerance half-life of approximately 3 days with full reset at 7 days^[15] — values consistent with the class but not verified for TMA-6 specifically.inferred

Cross-tolerance extends to other 5-HT₂A agonist psychedelics including LSD, psilocybin, mescaline, and the DOx series.^[4] Classical 5-HT₂A psychedelics generally lack abuse liability. No TMA-6-specific dependence studies exist, but the class profile supports characterization as non-habit-forming.

Drug Interactions

The critical interaction category is serotonergic potentiation, driven by TMA-6's dual 5-HT₂A agonist/MAO-A inhibitor mechanism.

Tryptamine psychedelics (DMT, psilocin, 5-MeO-DMT) are MAO substrates. Co-administration with TMA-6 could dramatically increase their potency and duration — a mechanism analogous to ayahuasca but uncontrolled and unpredictable.

Contraindications

No substance-specific contraindication data exist. The following are inferred from the compound's pharmacological profileinferred:

• Concurrent MAO inhibitor use — serotonin syndrome risk from combined MAO-A inhibition
• Concurrent SSRI/SNRI use — serotonin syndrome risk from impaired serotonin breakdown plus reuptake inhibitor
• Personal or family history of psychotic disorders — risk of psychotic episode precipitation
• Bipolar disorder — risk of manic episode precipitation
• Heart conditions — stimulant cardiovascular effects may worsen pre-existing conditions
• Pregnancy and breastfeeding — no safety data; theoretical risk to fetal development
• Liver impairment — expected liver-mediated metabolism may result in prolonged or unpredictable drug exposure

TMA-6 is controlled or banned in multiple jurisdictions, primarily through scheduling of the TMA series, novel psychoactive substance legislation, or structural analog provisions. In the United States, TMA-6 is classified as a Schedule I controlled substance as a positional isomer of 3,4,5-trimethoxyamphetamine (DEA code 7390). The Federal Analogue Act provides additional prosecution basis when TMA-6 is intended for human consumption, given structural similarity to mescaline.